Close
Drug Target Review – Outsmarting immune suppression through GPCR innovation
Why do so many solid tumors resist even the most advanced immunotherapies?
In Drug Target Review, our CSO Stephan Schann shared how we are addressing this challenge through our differentiated approach powered by deep expertise in GPCR biology, a proprietary platform, and a determination to transform patient outcomes.